Stockscreener 앱 받기
23.86
3.16%
0.73
시간 외 거래:
23.86
전일 마감가:
$23.13
열려 있는:
$22.9
하루 거래량:
1.22M
Relative Volume:
2.08
시가총액:
$1.40B
수익:
$1.23M
순이익/손실:
$-214.90M
주가수익비율:
-
EPS:
-
순현금흐름:
$-151.25M
1주 성능:
-1.08%
1개월 성능:
-13.24%
6개월 성능:
-6.91%
1년 성능:
+53.44%
1일 변동 폭
$22.62
$24.88
1주일 범위
$22.57
$25.67
52주 변동 폭
$15.60
$47.97
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
SYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
23.86 | 1.40B | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
State Street Corp Buys 131,896 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,680 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Earns Coveted Spot in Nasdaq Biotechnology Index, Marking IBD Innovation Leadership - StockTitan
Evercore ISI Group Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - MSN
Jones Trading Initiates Coverage of Spyre Therapeutics (SYRE) with Hold Recommendation - MSN
The Manufacturers Life Insurance Company Has $1.28 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics: Different Name, Same Tune (NASDAQ:SYRE) - Seeking Alpha
Wellington Management Group LLP Has $44.33 Million Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Charles Schwab Investment Management Inc. Has $9.80 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Eastern Progress Online
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Janus Henderson Group PLC - MarketBeat
61,256 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Cinctive Capital Management LP - MarketBeat
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $48.57 - MarketBeat
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire
Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodies - Yahoo Finance
Spyre begins Phase 1 trials for new IBD treatments By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Fmr LLC - MarketBeat
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies - PR Newswire
Walleye Capital LLC Increases Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LP - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation - AccessWire
SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect - AccessWire
Spyre Therapeutics’ $200 Million Common Stock Offering - Global Legal Chronicle
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect - AccessWire
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation - AccessWire
First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire
Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat
Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN
Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire
Spyre Therapeutics revises net loss per share calculations - Investing.com
Spyre Therapeutics launches $200 million public offering - Investing.com
Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan
Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat
Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com
SYRE Crosses Below Key Moving Average Level - Nasdaq
Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com
Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com
Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat
Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia
FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com
Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):